Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

Psoriasis News

the latest news from ipc, industry and others


Displaying 1 to 10 of 23 Posts . Displaying 10 of Posts . Page of 3 . Go To Page: . Per Page: . . . View All Sort By: .

IPC Councilors, César Gonzalez & Angela Londoño, contribute to publication on psoriasis en México

IPC Councilors, César Gonzalez & Angela Londoño, contribute to publication on conventional therapies in the time of biologics for Mexican journal, Dermatología.

Read More

IPC Think Tank addresses psoriasis "hot topics"

The IPC Think Tank is an annual event in which the organization’s key stakeholders gather to discuss the most pressing issues facing the clinical management and scientific understanding of psoriasis. Held this past December in Miami Beach, Florida, nearly 100 attendees participated in the meeting with representation from 17 countries.

Read More

IPC’s 2nd Master Class held in Barcelona, Spain

IPC President Jonathan Barker, United Kingdom, and IPC Board Member Lluís Puig, Spain, were co-chairs for IPC’s second Psoriasis Master Class, a comprehensive educational program IPC launched in early 2018 for dermatologists wanting to expand their expertise in caring for people with psoriasis.

Read More

TV Host and Fashion Journalist Louise Roe Shares Her Personal Story With Plaque Psoriasis as Part of INSIDE PERSPECTIVE Campaign

TV host and fashion journalist Louise Roe launches the INSIDE PERSPECTIVE campaign with Celgene Corporation (NASDAQ: CELG) and Otezla® (apremilast), and for the first time, shares her inside story with psoriasis, a condition she has been living with for more than a decade.

Read More

Sun Pharma Announces the Availability of ILUMYATM (tildrakizumab-asmn) in the United States for the Treatment of Moderate-to-Severe Plaque Psoriasis

Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associate companies) today announced that moderate-to-severe psoriasis treatment ILUMYATM (tildrakizumab-asmn) 100 mg/mL is now available in the United States. ILUMYATM is an injectable interleukin-23 (IL-23) inhibitor approved by the FDA for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Read More

The European Commission approves Almirall’s ILUMETRI® (tildrakizumab) for moderate-to-severe chronic plaque psoriasis

Almirall, S.A. announced today that the European Commission (EC) has approved ILUMETRI® (tildrakizumab), a humanized, high-affinity IL-23p19 monoclonal antibody, for the treatment of adult patients with moderate-to-severe chronic plaque psoriasis who are candidates for systemic therapy1.

Read More

Sienna Biopharmaceuticals Completes Maximal Use Safety Study of SNA-120 in Patients with Psoriasis

Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA), a clinical-stage medical dermatology and aesthetics company, today announced results from a Phase 1b maximal use (MUse) pharmacokinetic (PK) and safety study of SNA-120 (pegcantratinib), a Phase 2b drug candidate being evaluated as a topical, nonsteroidal therapy to treat itch (pruritus) associated with psoriasis.

Read More

IPC forum explores biosimilars at international conference

In July, IPC convened a Hot Topics Roundtable discussion on biosimilars, preceding the International Federation of Psoriasis Association’s 5th World Psoriasis & Psoriatic Arthritis Conference in Stockholm, Sweden.

Read More

Novartis receives FDA approval for inclusion of new evidence that Cosentyx® inhibits progression of joint structural damage in psoriatic arthritis

Novartis announced today that the US Food and Drug Administration (FDA) approved the inclusion of new evidence that Cosentyx® (secukinumab) significantly slows the progression of joint structural damage at Week 24 versus placebo in those with active psoriatic arthritis (PsA).

Read More

UCB Announces the Approval of CIMZIA® (certolizumab pegol) for Moderate-to-Severe Plaque Psoriasis, Representing an Important New Option for Patients in the U.S.

UCB announced today that the U.S. Food and Drug Administration (FDA) has approved extending the label for CIMZIA® (certolizumab pegol) to include a new indication in adults with moderate-to-severe plaque psoriasis.

Read More

Hot Topics in Psoriasis at AAD

february 28, 2019 
Washington D.C., USA
Register Now

Stay informed

Join the email list to receive the latest information on psoriasis meetings, manuscripts and research.

This website uses cookies. Please ensure your cookies are enabled.